• Surgical Critical Care
• Thoracic Surgery
• Duke university Medical Center - Cardiac Surgery
• St. Thomas' Hospital, London - Cardiology
• Duke University Medical Center - Surgery Research
• Duke University Medical Center - General & Thoracic Surgery
• Washington University School of Medicine, St. Louis - MD
Dr. Robinson, a native of Kansas, received his undergraduate B.A. degree at the University of Kansas and his medical degree from the Washington University School of Medicine in St. Louis, Missouri. He completed his internship and residency in general and cardiothoracic surgery at the Duke University Medical Center. Additionally, he completed a fellowship in cardiac research and clinical cardiac surgery at the St. Thomas’ Hospital in London. He also served as a Flight Surgeon at the rank of Major, USAF in Thailand during the Vietnam War.
A Diplomat of the American Board of Surgery, the American Board of Thoracic Surgery as well as certified in Surgical Critical Care, Dr. Robinson began his practice at the University of Nebraska Medical Center where he was an Associate Professor of Surgery and Pharmacology and the Clinical Director of the Clinical Perfusion Science Education Program. Dr. Robinson then came to the University of South Florida College of Medicine in Tampa in 1994 where he is currently a Professor of Surgery (Thoracic) and Interdisciplinary Oncology. He practices thoracic surgical oncology at the Moffitt Cancer Center as a Senior Member of the Moffitt Medical Group. He is also Co-Director of the Pancoast Tumor Program in the Department of Thoracic Oncology. Recently he was appointed Co-Director of the Center for Infection Research in Cancer (CIRC) which he helped found in 2012.
Dr. Robinson is the author or co-author of over 150 medical publications and he is directly involved in 3 clinical cancer research programs involving lung cancer and mesothelioma. At present he is Principal Investigator for a study using molecular methods searching for potential microorganisms that might cause or contribute to lung cancer. Clinically, he is a member of the multidisciplinary thoracic oncology group involved in the evaluation and treatment of all stages of lung cancer and mesothelioma, which includes aggressive, combined modality therapy.